We are at an inflection point that is driving a renaissance in antibody-drug conjugate (ADC) development. As successes in the clinic have led to more U.S. Food & Drug Administration (FDA) approvals, ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm ...

Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around 7 to 8. This is much higher than the DAR’s of older generations of ADCs, which ...

on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate ...

In classical bacterial conjugation, one bacterium transfers genetic material to another through direct cell-to-cell contact.3 This can either be through a natural process or via artificial means.

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients.

GSK’227 (also known as HS-20093) is a novel antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

Pfizer doubles down on AI partnership with antibody-drug conjugate deal Artificial intelligence start-up PostEra will help the drugmaker design new payloads by Rowan Walrath January 7, 2025 ...

Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes ...

Pneumococcal conjugate vaccines have proved to be highly effective in reducing vaccine-type pneumococcal disease. 1-3 Since 2010, Gavi, the Vaccine Alliance, has funded introduction of ...